229 related articles for article (PubMed ID: 32654064)
21. Treatment Outcomes With Rituximab in 100 Patients With Neuromyelitis Optica: Influence of FCGR3A Polymorphisms on the Therapeutic Response to Rituximab.
Kim SH; Jeong IH; Hyun JW; Joung A; Jo HJ; Hwang SH; Yun S; Joo J; Kim HJ
JAMA Neurol; 2015 Sep; 72(9):989-95. PubMed ID: 26167726
[TBL] [Abstract][Full Text] [Related]
22. Evaluation of treatment response in adults with relapsing MOG-Ab-associated disease.
Cobo-Calvo A; Sepúlveda M; Rollot F; Armangué T; Ruiz A; Maillart E; Papeix C; Audoin B; Zephir H; Biotti D; Ciron J; Durand-Dubief F; Collongues N; Ayrignac X; Labauge P; Thouvenot E; Bourre B; Montcuquet A; Cohen M; Deschamps R; Solà-Valls N; Llufriu S; De Seze J; Blanco Y; Vukusic S; Saiz A; Marignier R
J Neuroinflammation; 2019 Jul; 16(1):134. PubMed ID: 31266527
[TBL] [Abstract][Full Text] [Related]
23. Effectiveness and safety of Rituximab in demyelinating diseases spectrum: An Italian experience.
D'Amico E; Zanghì A; Chisari CG; Fermo SL; Toscano S; Arena S; Patti F; Zappia M
Mult Scler Relat Disord; 2019 Jan; 27():324-326. PubMed ID: 30471585
[TBL] [Abstract][Full Text] [Related]
24. Treatment of neuromyelitis optica with rituximab: a 2-year prospective multicenter study.
Cabre P; Mejdoubi M; Jeannin S; Merle H; Plumelle Y; Cavillon G; Smadja D; Marignier R;
J Neurol; 2018 Apr; 265(4):917-925. PubMed ID: 29455361
[TBL] [Abstract][Full Text] [Related]
25. COVID-19 in 7 multiple sclerosis patients in treatment with ANTI-CD20 therapies.
Meca-Lallana V; Aguirre C; Beatrizdel Río ; Cardeñoso L; Alarcon T; Vivancos J
Mult Scler Relat Disord; 2020 Sep; 44():102306. PubMed ID: 32585617
[TBL] [Abstract][Full Text] [Related]
26. Less frequent rituximab retreatment maintains remission of neuromyelitis optica spectrum disorder, following long-term rituximab treatment.
Kim SH; Kim Y; Kim G; Park NY; Jang HM; Shin HJ; Hyun JW; Kim HJ
J Neurol Neurosurg Psychiatry; 2019 Apr; 90(4):486-487. PubMed ID: 29929977
[No Abstract] [Full Text] [Related]
27. Early relapse after RTX initiation in a patient with NMO/MS overlap syndrome: How long to conclude to a failure treatment?
Maillart E; Lippi A; Lubetzki C; Louapre C; Papeix C
Mult Scler Relat Disord; 2018 Feb; 20():220-222. PubMed ID: 29433095
[TBL] [Abstract][Full Text] [Related]
28. Effective suppression of cerebrospinal fluid B cells by rituximab and cyclophosphamide in progressive multiple sclerosis.
Petereit HF; Rubbert A
Arch Neurol; 2005 Oct; 62(10):1641-2; author reply 1642. PubMed ID: 16216954
[No Abstract] [Full Text] [Related]
29. Individualized B cell-targeting therapy for neuromyelitis optica spectrum disorder.
Kim SH; Hyun JW; Kim HJ
Neurochem Int; 2019 Nov; 130():104347. PubMed ID: 30513364
[TBL] [Abstract][Full Text] [Related]
30. Prolonged Remission in Neuromyelitis Optica Following Cessation of Rituximab Treatment.
Weinfurtner K; Graves J; Ness J; Krupp L; Milazzo M; Waubant E
J Child Neurol; 2015 Sep; 30(10):1366-70. PubMed ID: 25387545
[TBL] [Abstract][Full Text] [Related]
31. Rituximab-induced interstitial lung disease in a patient with aquaporin-4 immunoglobulin G-positive neuromyelitis optica spectrum disorder.
Ahn SH; Kim SM; Sung JJ
Mult Scler Relat Disord; 2018 Feb; 20():192-193. PubMed ID: 29414297
[TBL] [Abstract][Full Text] [Related]
32. Relapsing neuromyelitis optica responsive to glatiramer acetate treatment.
Gartzen K; Limmroth V; Putzki N
Eur J Neurol; 2007 Jun; 14(6):e12-3. PubMed ID: 17539924
[No Abstract] [Full Text] [Related]
33. Variable responses to rituximab treatment in neuromyelitis optica (Devic's disease).
Capobianco M; Malucchi S; di Sapio A; Gilli F; Sala A; Bottero R; Marnetto F; Doriguzzi Bozzo C; Bertolotto A
Neurol Sci; 2007 Aug; 28(4):209-11. PubMed ID: 17690854
[TBL] [Abstract][Full Text] [Related]
34. Further support for rituximab in relapsing multiple sclerosis.
Naismith RT; Cross AH
Lancet Neurol; 2022 Aug; 21(8):672-673. PubMed ID: 35841895
[No Abstract] [Full Text] [Related]
35. Maximally tolerated versus minimally effective dose: the case of rituximab in multiple sclerosis.
Nielsen AS; Miravalle A; Langer-Gould A; Cooper J; Edwards KR; Kinkel RP
Mult Scler; 2012 Mar; 18(3):377-8. PubMed ID: 21828201
[No Abstract] [Full Text] [Related]
36. Rituximab for relapsing-remitting multiple sclerosis.
He D; Guo R; Zhang F; Zhang C; Dong S; Zhou H
Cochrane Database Syst Rev; 2013 Dec; (12):CD009130. PubMed ID: 24310855
[TBL] [Abstract][Full Text] [Related]
37. Changes in B and T-cell subsets and NMO-IgG levels after immunoglobulins and rituximab treatment for an acute attack of neuromyelitis optica.
de Andrés C; Teijeiro R; Saiz A; Fernández P; Sánchez-Ramón S
Neurologia; 2015 Jun; 30(5):276-82. PubMed ID: 24674779
[TBL] [Abstract][Full Text] [Related]
38. Rituximab in relapsing-remitting multiple sclerosis.
Chaudhuri A; Behan PO
N Engl J Med; 2008 Jun; 358(24):2646; author reply 2646-7. PubMed ID: 18557178
[No Abstract] [Full Text] [Related]
39. Management of Fulminant Multiple Sclerosis With Rituximab: A Case Report.
Parfenov V; Du Pasquier R; Schluep M
Neurologist; 2015 Jun; 19(6):155-7. PubMed ID: 26075469
[TBL] [Abstract][Full Text] [Related]
40. Course of neuromyelitis optica during inadvertent pregnancy in a patient treated with rituximab.
Pellkofer HL; Suessmair C; Schulze A; Hohlfeld R; Kuempfel T
Mult Scler; 2009 Aug; 15(8):1006-8. PubMed ID: 19667025
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
